Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Docetaxel (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Dec 2017.
    • 29 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 11 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top